Research graph
References from Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB). Local targets link to admitted publications; unresolved targets remain external evidence.
The role of liquid biopsy as a catalyst for sustained progress in precision oncology – perspective of the young committee of the international society of liquid biopsy
10.1016/j.jlb.2024.100156 · 2024 · External reference
Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
10.1038/s41698-025-00876-y · 2025 · External reference
Unveiling the impact of circulating tumor cells: two decades of discovery and clinical advancements in solid tumors
10.1016/j.critrevonc.2024.104483 · 2024 · External reference
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group
10.1016/j.annonc.2022.05.520 · 2022 · External reference
A scoping review of factors influencing the implementation of liquid biopsy for cancer care
10.1186/s13046-025-03322-w · 2025 · External reference
Recommendations for the equitable and widespread implementation of liquid biopsy for cancer care
10.1200/po.23.00382 · 2024 · External reference
Clinical use of liquid biopsy in metastatic breast cancer—an ESSO‐EYSAC international survey
10.1002/jso.70045 · 2025 · External reference
Assessing oncologists' attitudes concerning comprehensive genomic profiling in stage IV lung adenocarcinoma in Brazil
2022 · External reference
US physician perspective on the use of biomarker and ctDNA testing in patients with melanoma
10.1016/j.critrevonc.2024.104289 · 2024 · External reference
The current status of circulating tumor DNA utilization in Australasia: a survey of thoracic oncology group Australasia members
10.1111/ajco.14215 · 2026 · External reference
Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: a bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey
10.1016/j.clinre.2021.101681 · 2021 · External reference
Translating ctDNA into cutaneous melanoma care: an international expert survey
10.1016/j.ejca.2026.116676 · 2026 · External reference
The 2024 international association for the study of lung cancer global survey on biomarker testing
10.1016/j.jtho.2025.07.114 · 2025 · External reference
ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe
10.1016/j.annonc.2023.06.011 · 2023 · External reference
ESMO international consortium study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
10.1093/annonc/mdx521 · 2017 · External reference
Private payer and medicare coverage policies for use of circulating tumor DNA tests in cancer diagnostics and treatment
10.6004/jnccn.2023.7011 · 2023 · External reference
Limited genomics training among physicians remains a barrier to genomics-based implementation of precision medicine
10.3389/fmed.2022.757212 · 2022 · External reference
Cancer in a drop: advances in liquid biopsy in 2024
10.1016/j.critrevonc.2025.104776 · 2025 · External reference
International expert consensus on the clinical integration of circulating tumor cells in solid tumors
10.1016/j.ejca.2025.116050 · 2025 · External reference
Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancer
10.1038/s41416-024-02709-4 · 2024 · External reference
International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors
10.1016/j.jlb.2025.100301 · 2025 · External reference
Developing consensus for a more provider-friendly next-generation sequencing molecular biomarker report: a joint consensus recommendation of the association for molecular pathology and college of American pathologists
10.1016/j.jmoldx.2025.08.011 · 2025 · External reference
Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer
10.1136/esmoopen-2018-000398 · 2018 · External reference
Analysis of the cost-effectiveness of liquid biopsy to determine treatment change in patients with Her2-Positive advanced breast cancer in Colombia
10.2147/ceor.s220726 · 2020 · External reference
Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach
10.1007/s00432-022-04034-w · 2023 · External reference
Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (Liquid Biopsy) vs fecal tests or colonoscopy
10.1053/j.gastro.2024.03.011 · 2024 · External reference
The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population
10.1016/j.lungcan.2024.107794 · 2024 · External reference
Explorative cost-effectiveness analysis of colorectal cancer recurrence detection with next-generation sequencing liquid biopsy in Spain, France, and Germany
10.1177/17562848241248246 · 2024 · External reference
Use of real-world evidence in US payer coverage decision-making for next-generation sequencing–based tests: challenges, opportunities, and potential solutions
10.1016/j.jval.2020.02.001 · 2020 · External reference
Financing and reimbursement models for personalised medicine: a systematic review to identify current models and future options
10.1007/s40258-021-00714-9 · 2022 · External reference
Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps
10.1038/s41698-025-00865-1 · 2025 · External reference
Challenges and opportunities of cfDNA analysis implementation in clinical practice: perspective of the international society of liquid biopsy (ISLB)
10.1016/j.critrevonc.2020.102978 · 2020 · External reference
